ABIONYX Pharma Reports Stable First Quarter and Robust Financing for Future Growth

ABIONYX Pharma reported consolidated revenue of €0.8 million for the first quarter of 2026, noting a slight dip from the previous year. With €2.6 million in secured business, the company maintains commercial visibility for the year. However, its core strategic initiatives, particularly in compassionate use applications, did not generate revenue as the products were provided free of charge.

At the end of March 2026, the company held stable cash reserves of €2.8 million, mirroring the end-of-year figures for 2025, with a boost anticipated from research tax credits totaling €0.7 million. Additionally, ABIONYX announced a €18.7 million capital increase and non-dilutive bond financing, ensuring financial resources through 2028. This funding supports key milestones including the marketing application for CER-001 in LCAT deficiency and the Phase 2b sepsis trial.